Carmine Therapeutics is a biotechnology company focused on harnessing the unique properties of red blood cell extracellular vesicles (RBCEVs) to develop powerful, non-viral gene therapies. Their proprietary REGENT™ platform aims to overcome the limitations of current viral-based gene therapies, offering the potential for repeat dosing, larger payload capacity, and a better safety profile. Carmine is advancing a pipeline of therapeutics for a range of genetic and rare diseases, with a mission to deliver transformative treatments to patients in need.
Serves as the primary center for corporate strategy, research leadership, business development, clinical operations, and administrative functions.
Situated within a vibrant biotech hub, providing access to state-of-the-art laboratory facilities and a collaborative ecosystem of research institutions and partner companies.
A science-driven, innovative, and collaborative environment. Employees are typically passionate about advancing gene therapy and making a difference in patients' lives, working in a fast-paced, dynamic setting.
The Cambridge location provides unparalleled access to top-tier talent, leading academic research, venture capital, and potential pharmaceutical partners, crucial for a pioneering biotech firm.
Carmine Therapeutics operates with key research and development hubs in North America (Cambridge, MA) and Asia (Singapore). This dual presence allows them to leverage talent, resources, and collaborative opportunities in two major global biotech centers, supporting their efforts in platform development, pipeline advancement, and strategic partnerships worldwide.
200 Technology Square, Suite 230
Cambridge
MA
USA
Address: Discovery Centre, 45 Nanyang Drive, #02-02, Singapore 637460 (Note: This is an address associated with EVX Ventures, a key founder/investor; specific Carmine R&D site in Singapore may be within a research park like Biopolis or associated with NUS Enterprise)
To advance core RBCEV technology, foster collaborations within the Asia-Pacific biotech ecosystem, and support global R&D programs. Taps into Singapore's strong biomedical research infrastructure.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Carmine Therapeutics' leadership includes:
Carmine Therapeutics has been backed by several prominent investors over the years, including:
In the past 12-18 months, Carmine Therapeutics appointed its co-founder Xingfeng Bao as CEO and strengthened its clinical development capabilities with the hiring of Eliseo Salinas as Chief Development Officer.
Discover the tools Carmine Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While not publicly confirmed, biotechnology companies of Carmine Therapeutics's size often use common email patterns. The most likely format is [first_initial][last]@carminetherapeutics.com or [first].[last]@carminetherapeutics.com.
[first_initial][last]@carminetherapeutics.com
Format
xbao@carminetherapeutics.com
Example
70%
Success rate
PR Newswire • May 16, 2023
Carmine Therapeutics announced the appointment of Eliseo Salinas, MD, MSc, as its Chief Development Officer. Dr. Salinas brings extensive experience in clinical development and regulatory affairs to lead Carmine's efforts in advancing its novel gene therapies through clinical trials....more
PR Newswire • January 05, 2023
Carmine Therapeutics announced that its Board of Directors has appointed Co-founder Xingfeng Bao, Ph.D., as Chief Executive Officer, effective immediately. He succeeds Don Haut, Ph.D., who will transition from the Company....more
Takeda • March 30, 2021
Carmine Therapeutics and Takeda Pharmaceutical Company Limited announced a research collaboration and license agreement to discover, develop, and commercialize non-viral gene therapies for two rare disease targets using Carmine's REGENT™ Platform. The deal included upfront payment, milestones up to $900M and royalties....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Carmine Therapeutics, are just a search away.